Pancreatic Cancer Research

ResearcherSemmelweis UniversityActive in the last 2 years

Albrecht Neeße

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3690-1957; OpenAlex author ID A5014477435. Sources: OpenAlex.

Their work

Papers
39 (first author 1, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
113
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 4 papers · 2014: 3 papers · 2015: 5 papers · 2016: 3 papers · 2017: none · 2018: 1 paper · 2019: 6 papers · 2020: 3 papers · 2021: 2 papers · 2022: 3 papers · 2023: 1 paper · 2024: 3 papers · 2025: none · 2026: 1 paper

Papers 39

  1. Benchmarking the Intratumoral Microbiome in Pancreatic Ductal Adenocarcinoma: A Longitudinal Assessment of Contamination Sources and Decontamination Strategies Co-author DOI 10.64898/2026.08.24.746744↗
  2. Expression of gemcitabine metabolizing enzymes and stromal components reveal complexities of preclinical pancreatic cancer models for therapeutic testing. Last author DOI 10.1016/j.neo.2024.101002↗
  3. An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies. Co-author DOI 10.1053/j.gastro.2023.10.026↗
  4. Scribble Deficiency Promotes Pancreatic Ductal Adenocarcinoma Development and Metastasis. Co-author DOI 10.1158/0008-5472.can-23-3419↗
  5. Dynamics of intestinal and intratumoral microbiome signatures in genetically engineered mice and human pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2023.07.008↗
  6. Axon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancer. Co-author DOI 10.1172/jci.insight.154475↗
  7. TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer. Co-author DOI 10.3390/cancers14143451↗
  8. The Microbiome in PDAC-Vantage Point for Future Therapies? Co-author DOI 10.3390/cancers14235974↗
  9. TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer. Co-author DOI 10.1038/s43018-021-00258-w↗
  10. Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer. Co-author DOI 10.3390/cells10123463↗
  11. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-020-0846-2↗
  12. Microenvironmental Determinants of Pancreatic Cancer. Last author DOI 10.1152/physrev.00042.2019↗
  13. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6. Co-author DOI 10.1158/0008-5472.can-20-0672↗
  14. Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites. Last author DOI 10.1016/j.ebiom.2019.01.037↗
  15. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Co-author DOI 10.1016/j.pan.2018.10.003↗
  16. Stromal biology and therapy in pancreatic cancer: ready for clinical translation? Co-author DOI 10.1136/gutjnl-2018-316451↗
  17. A tangled tale of molecular subtypes in pancreatic cancer. Last author DOI 10.1136/gutjnl-2018-318086↗
  18. Preclinical Evaluation of 1,2-Diamino-4,5-Dibromobenzene in Genetically Engineered Mouse Models of Pancreatic Cancer. Last author DOI 10.3390/cells8060563↗
  19. Stromal Features of the Primary Tumor Are Not Prognostic in Genetically Engineered Mice of Pancreatic Cancer. Last author DOI 10.3390/cells9010058↗
  20. Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models. Last author DOI 10.3791/56979↗
  21. ETS-Transcription Factor ETV1 Regulates Stromal Expansion and Metastasis in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2016.06.005↗
  22. GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression. Last author DOI 10.1158/1535-7163.mct-15-0309↗
  23. Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study. Co-author DOI 10.1159/000453257↗
  24. [Pancreatic cancer stroma: oncologist's ally or foe?]. Co-author DOI 10.1055/s-0034-1398955↗
  25. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Co-author DOI 10.1136/gutjnl-2015-309304↗
  26. Emerging role of microRNAs to tackle drug resistance in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2015-309503↗
  27. New Advances in the Treatment of Metastatic Pancreatic Cancer. Co-author DOI 10.1159/000439523↗
  28. Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity. Co-author DOI 10.15252/embj.201489574↗
  29. Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo. Co-author DOI 10.1038/bjc.2014.288↗
  30. nab-Paclitaxel: novel clinical and experimental evidence in pancreatic cancer. Co-author DOI 10.1055/s-0034-1366002↗
  31. Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. Co-author DOI 10.1158/2159-8290.cd-13-0593↗
  32. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2012-302529↗
  33. Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions. Co-author DOI 10.1136/gutjnl-2012-302577↗
  34. Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer. Co-author DOI 10.1371/journal.pone.0067330↗
  35. Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Co-author DOI 10.2147/ott.s38111↗
  36. Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials. Co-author DOI 10.1016/j.pan.2011.12.009↗
  37. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. First author DOI 10.1158/2159-8290.cd-11-0242↗
  38. Therapeutic targeting of apoptotic pathways: novel aspects in pancreatic cancer. Co-author DOI 10.2174/138920112802501953↗
  39. Stromal biology and therapy in pancreatic cancer. Co-author DOI 10.1136/gut.2010.226092↗

Closest collaborators

The 25 strongest of 113 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Volker Ellenrieder · 19 shared papers, 2014–2026 · strength 2.18
  2. Elisabeth Heßmann · 14 shared papers, 2014–2024 · strength 1.40
  3. Shiv K. Singh · 13 shared papers, 2014–2024 · strength 1.39
  4. Christoph Ammer‐Herrmenau · 5 shared papers, 2022–2026 · strength 1.05
  5. David Arthur Tuveson · 14 shared papers, 2011–2024 · strength 0.76
  6. Thomas Mathias Gress · 10 shared papers, 2011–2020 · strength 0.64
  7. Shilpa Patil · 6 shared papers, 2018–2022 · strength 0.60
  8. Linh Dang · 2 shared papers, 2022–2026 · strength 0.49
  9. Lennart Versemann · 4 shared papers, 2020–2024 · strength 0.48
  10. Robert G. Goetze · 4 shared papers, 2018–2024 · strength 0.46
  11. Nina Pfisterer · 2 shared papers, 2022–2023 · strength 0.40
  12. Marie C. Hasselluhn · 3 shared papers, 2019–2024 · strength 0.40
  13. Lukas Klein · 3 shared papers, 2019–2022 · strength 0.32
  14. Patrick Michl · 6 shared papers, 2011–2019 · strength 0.32
  15. Jochen Gaedcke · 4 shared papers, 2015–2021 · strength 0.32
  16. Duncan Ian Jodrell · 7 shared papers, 2012–2020 · strength 0.31
  17. Steven A. Johnsen · 3 shared papers, 2019–2024 · strength 0.29
  18. Stephan A. Hahn · 3 shared papers, 2013–2024 · strength 0.26
  19. Daniel Öhlund · 2 shared papers, 2019–2024 · strength 0.26
  20. Alexander Otto König · 4 shared papers, 2014–2024 · strength 0.25
  21. Thomas Knösel · 2 shared papers, 2019–2024 · strength 0.24
  22. Christian P. Pilarsky · 2 shared papers, 2019–2024 · strength 0.24
  23. Sebastian Krug · 4 shared papers, 2013–2019 · strength 0.23
  24. Elisa Espinet · 2 shared papers, 2021–2022 · strength 0.22
  25. Uday Kishore · 2 shared papers, 2021–2022 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.